妖姬直播

Greg Laub

Greg Laub

Authors >

Greg Laub

Greg Laub joined 妖姬直播 in 2005 as Production Manager and led the launch of the video department in 2007. He currently leads the video and podcast production teams. Greg's passion to craft a story began as a writer, with stops as Managing Editor at USOpen.org, Creative Director at Bernard Hodes Advertising, and copywriter at AOL Time Warner. He's even had one of his screenplays produced -- he believes it was beloved by all seven people who saw it. Greg lives in New Jersey with his wife, two kids and two dogs.

Connect:

email image

Latest from Greg Laub

Innovative Caregiver Support Program Shines at Alzheimer's Conference

Florida's partnership sets a national example in supporting families caring for loved ones

Finding That APOE4 Is Toxic in Alzheimer's Can Help Guide Targeted Therapies

Differing risk of APOE4 between ethnic backgrounds also may come into play

Mild Cognitive Impairment Tied to Delayed Responses in Gaze and Speech

Study suggests gaze and speech behaviors differ from healthy controls

Uncovering Why Studying Diverse Populations Is Crucial to Alzheimer's Research

Lessons from the Alzheimer's Disease Sequencing Project and subsequent DAWN study

Virtual Palliative Care Improves Quality of Life in Advanced Lung Cancer

Video consultations had equivalent effects to in-person visits

Embracing Subcutaneous Drugs in Lung Cancer and Beyond

Patients by far prefer subcutaneous to intravenous medication delivery, says Jorge Nieva, MD

A Closer Look at the Innovative Pragmatica-Lung Trial

Streamlined approach broadens eligibility and reduces site burden

Osimertinib Yields 'Phenomenal' Gains in PFS for Stage III EGFR-Mutant NSCLC

And minimal residual disease analysis may help determine length of therapy

Experts Discuss the Latest Studies on ADCs for Lung Cancer at ASCO 2024

Panelists talk about where lung cancer research will be in 5 years

Highlights in Metastatic Breast Cancer: Key Findings From ASCO 2024

Haten Soliman, MD, talks about advancements in early treatment and CDK4/6 inhibitors

1

鈥�